Article Text

other Versions

Predictors of cognitive and psychosocial outcome after STN DBS in Parkinson Disease
  1. Harriet M M Smeding (h.m.smeding{at}
  1. Academic Medical Center, Netherlands
    1. Johannes D Speelman (j.d.speelman{at}
    1. Academic Medical Center, Netherlands
      1. Hilde M Huizenga (h.m.huizenga{at}
      1. Department of Psychology, University of Amsterdam, Netherlands
        1. P Richard Schuurman (p.r.schuurman{at}
        1. Academic Medical Center, Netherlands
          1. Ben Schmand (b.schmand{at}
          1. Academic Med Center/Univ of Amsterdam, Netherlands


            Objective: To find predictors of cognitive decline and quality of life one year after bilateral subthalamic nucleus stimulation (STN DBS) in Parkinson’s disease (PD).

            Methods: A total of 105 patients were evaluated with a comprehensive neuropsychological assessment before and 12 months after surgery. A control group of 40 PD patients was included to control for effects of repeated testing and disease progression. We determined individual changes in cognition, mood and quality of life using a statistical method that controls for multiple comparisons. We performed logistic regression analyses to assess predictors of cognitive changes and quality of life.

            Results: Twelve months after surgery, the improvement in motor function was 41% (UPDRS3 score in off). The STN group showed a large improvement in quality of life compared to the control group (Cohen’s d=0.9). At the individual level, 32 percent (95% CI: 22 – 40) of the STN group showed a substantial improvement in quality of life. Thirty six percent (95% CI: 27 - 46) of the STN patients showed a profile of cognitive decline compared to the control group. Mood improved in 16 STN patients and declined in 16 subjects. Impaired attention, advanced age and a low levodopa response at baseline predicted cognitive decline, whereas a high levodopa response at baseline predicted improvement in quality of life. Postoperative decrease in dopaminergic medication was not related to cognitive decline.

            Conclusions: STN DBS improves quality of life. However, a profile of cognitive decline can be found in a significant number of patients. Levodopa response, age and attention at baseline are predictors of cognitive and psychosocial outcome.

            Statistics from

            Request Permissions

            If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.